Livagen Preclinical

What It Is

Livagen is a synthetic tetrapeptide composed of the amino acid sequence Lys-Glu-Asp-Ala (abbreviated KEDA in the Khavinson literature). It is part of the short-peptide bioregulator family developed at the St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson and colleagues, who have argued since the 1980s that extractable low-molecular-weight peptide fractions from specific organs retain the "regulatory information" of the source tissue and can be used to normalize function in corresponding tissues across aging and disease. Livagen was initially derived from studies of peptide fractions of lymphoid tissue and subsequently framed as a lymphoid and hepatic bioregulator — the "liv-" prefix evokes both "liver" and "livestock / spleen" origins across different Khavinson-era publications.

The Khavinson-group research program has produced a broad family of short peptides — Epithalon (tetrapeptide, pineal), Pinealon (tripeptide, CNS), Vilon (KE dipeptide, thymic), Thymogen (Glu-Trp, thymic), Pancragen (KEDW, pancreatic), Vesugen (KED, vascular), Livagen (KEDA, lymphoid/hepatic), and others — each assigned a target-tissue identity based on the parent tissue extract. Synthetic KEDA was subsequently claimed to reproduce the effects of the parent lymphoid/hepatic polypeptide extract. Critically, most clinical data originates from the source tissue extract preparations used in Russian clinical practice (organopreparations of the "Thymalin / Epithalamin / Cortexin" generation), and the synthetic short peptides are positioned as the "bioregulator active principle" recapitulating those effects.

Livagen's best-studied claim is a proposed role in chromatin regulation. Multiple papers from the Khavinson group describe short peptides — including KEDA — penetrating nuclei of cultured cells (including HeLa cells in the Fedoreyeva 2011 Biochemistry Moscow study), binding to histone-associated DNA sequences, and producing decondensation of heterochromatin visible by fluorescence microscopy. The proposed downstream consequence is reactivation of "age-silenced" genes and normalization of tissue-specific function. This is the most mechanistically concrete piece of the Khavinson peptide framework, though independent-group replication remains limited.

As of April 2026, Livagen is commercially available in Russia and former-Soviet pharmacies as an over-the-counter dietary bioregulator, frequently in short-course (10–20 day) capsule or sublingual regimens. It is not approved by the US FDA, EMA, MHRA, or other major Western regulatory authorities. Outside Russia and its periphery, Livagen circulates primarily through longevity-focused research-peptide supply channels and a small off-label practitioner community.

Mechanism of Action

The Khavinson group's mechanistic framework proposes several convergent actions for KEDA. These claims are primarily supported by in vitro and rodent preclinical work from the St. Petersburg group.

• Nuclear penetration (PepT / non-PepT pathways) — Short Khavinson peptides have been shown to penetrate the cellular and nuclear membrane of cultured cells. Fedoreyeva et al. (Biochemistry Moscow 2011) demonstrated fluorescence-labeled short peptides (including AEDG / Epithalon and related tetrapeptides) localizing to the nucleus of HeLa cells. The uptake mechanism is not fully characterized; PepT1-like oligopeptide transport and direct membrane penetration have both been proposed.
• Site-specific DNA binding — Khavinson and colleagues report that short peptides including KEDA bind specific double-stranded DNA sequences (proposed recognition of 6–9-bp sequences matching the peptide's "chemical complement"), hypothesizing that these peptide-DNA interactions modulate local chromatin structure.
• Heterochromatin decondensation — Fluorescence-microscopy studies by the Khavinson group report that KEDA induces visible decondensation of condensed heterochromatin domains in lymphocyte and hepatocyte nuclei. The proposed functional consequence is re-exposure of silenced genes, permitting transcription of previously suppressed regions.
• Tissue-specific gene expression modulation — In hepatocytes, treated cells reportedly upregulate expression of albumin, cytochrome P450 enzymes (Phase I detoxification), glutathione transferases (Phase II), and regeneration-associated genes. In lymphoid tissue, similar upregulation of functional lymphoid gene programs has been reported.
• Hepatoprotective signaling — In animal models of toxic or ischemic liver injury, Livagen/KEDA treatment is reported to reduce transaminase elevation, improve histological recovery, and accelerate hepatocyte proliferation after partial hepatectomy or chemical injury.
• Immunomodulation / lymphoid normalization — Livagen is also framed as a lymphoid bioregulator, reportedly normalizing T-cell and B-cell populations and restoring functional immune responses in immunosenescent rodent models and in elderly human cohorts (Russian clinical observation data).
• Antioxidant enzyme upregulation — Consistent with other Khavinson peptides, Livagen treatment reportedly increases superoxide dismutase (SOD), catalase, and glutathione peroxidase activity in target tissues, providing a proposed second-order antioxidant mechanism downstream of gene-expression modulation.
• Short-course "bioregulation" pharmacology — The proposed pharmacology is episodic rather than chronic: 10–20-day courses are argued to reset tissue-specific gene expression patterns, with benefits persisting for weeks-to-months after cessation. This is the signature Khavinson-framework dosing model.

What the Research Shows

The Livagen / KEDA evidence base is almost entirely preclinical and almost entirely generated by the Khavinson group and close collaborators. Western independent replication remains limited. The following captures the main published claims.

• Short-peptide nuclear penetration (Fedoreyeva et al., Biochemistry Moscow 2011; PMID 22117546) — Fluorescence-labeled short Khavinson peptides localize to the nucleus of HeLa cells in culture. Foundational evidence supporting direct nuclear action of short peptides.
• Chromatin decondensation in hepatocyte nuclei — Khavinson-group publications (Bulletin of Experimental Biology and Medicine and Russian-language journals, 2007–2012) describe KEDA-induced decondensation of heterochromatin in hepatocyte nuclei by fluorescence microscopy and atomic force microscopy.
• Hepatic gene expression modulation — Papers from the Khavinson group report Livagen-induced upregulation of albumin, CYP450, and detoxification-enzyme expression in hepatocyte culture and in animal liver tissue.
• Hepatic regeneration models — Partial hepatectomy rodent models treated with Livagen or the parent liver peptide extract reportedly show accelerated hepatocyte proliferation and faster functional recovery.
• Hepatotoxicity protection — Animal models of CCl₄-induced and ethanol-induced hepatotoxicity treated with Livagen or parent extract show improved transaminases and histology compared to untreated controls in Khavinson-group reports.
• Lymphocyte function normalization (Khavinson group) — Elderly-cohort observational data and rodent immunosenescence models report normalization of T-cell subsets and functional immune responses after short courses of KEDA or parent lymphoid extract.
• Parent tissue extract clinical experience (Russian hepatology) — Livagen's parent liver polypeptide extract has decades of use in Russian hepatology for chronic hepatitis, cirrhosis support, and post-toxic recovery. This is not the same molecule as synthetic KEDA, but the Khavinson framework argues they are mechanistically convergent.
• Khavinson general framework reviews (Neuroendocrinology Letters 2002; Karger monograph 2005) — Extensive programmatic reviews of the full peptide-bioregulator framework, including KEDA and related tetrapeptides, published by Khavinson and colleagues.
• Limited independent Western replication — Unlike some other Khavinson peptides (notably Thymosin α1, which has extensive independent characterization), KEDA has received minimal attention from non-Khavinson-affiliated Western laboratories as of publication.
• No Phase 2 or Phase 3 clinical trial — No randomized, placebo-controlled clinical trial of synthetic KEDA meeting modern regulatory standards has been published in peer-reviewed English-language literature.

Human Data

Human evidence for synthetic Livagen is limited:

• No peer-reviewed RCT of synthetic KEDA — Search of major databases identifies no randomized, placebo-controlled clinical trial of the synthetic tetrapeptide meeting modern regulatory standards.
• Parent polypeptide extract clinical experience — Liver polypeptide extracts (the "Sireparum" / "Hepatamine" / liver-tissue-derived organopreparations) have long Russian clinical use, but these are complex biological extracts rather than the defined-structure synthetic KEDA peptide.
• Russian observational cohort reports — Papers from Russian clinical practice describe short-course KEDA administration in elderly patients with chronic hepatitis, fatty liver disease, and post-toxic recovery, reporting improvement in subjective symptoms, transaminase normalization, and immune-marker recovery. These reports do not meet Western randomized-controlled-trial methodological standards.
• Dietary-bioregulator registration (Russia) — Livagen is registered and marketed in Russia as an over-the-counter dietary bioregulator, not as a prescription drug. This regulatory category does not require the controlled-efficacy data that drug approval would require.
• No FDA / EMA / MHRA submission — Livagen has not been submitted for regulatory review in the US, EU, or UK at publication.
• Community / longevity-practitioner experience — Accumulated off-label practitioner experience exists but is observational, highly heterogeneous, and has not been systematically aggregated in peer-reviewed literature.

The honest read: the human data on synthetic Livagen is sufficient to support its continued investigational use in Russia but is insufficient to support therapeutic claims outside that regulatory context. Patients using Livagen in the Western community peptide space are relying on the Khavinson preclinical framework plus the parent-extract clinical tradition, neither of which is equivalent to modern clinical trial data on the synthetic tetrapeptide.

Dosing from the Literature

Khavinson-style dosing is the standard framework — short courses of 10–20 days, repeated 2–3 times per year. Oral/sublingual capsule and injectable (SubQ or IM) routes are both described in Russian clinical practice.

Reconstitution & Storage

Synthetic Livagen is supplied either as pre-formulated capsules (Russian retail product) or as lyophilized powder in research-chemical vials (typical research-peptide supply).

• Reconstitution — Add bacteriostatic water slowly down the vial wall at 45°; swirl gently, do not shake. Solution should be clear.
• Oral capsule — The Russian retail product is typically supplied as 10–20 mg capsules taken before meals. Bypasses the need for reconstitution.
• Sublingual administration — Some practitioners administer reconstituted Livagen sublingually, holding the volume under the tongue for 30–60 seconds before swallowing; the mucosal / swallowed mix is poorly characterized but may leverage oligopeptide transport.
• Storage — Lyophilized vials: long-term at −20°C, short-term at 2–8°C. Reconstituted solution: 2–8°C, use within 14–21 days given the short peptide's modest solution stability.
• Inspection — Discard if cloudy, discolored, or particulate.

→ Use the Kalios Dosing Calculator for Livagen volume conversions

Side Effects & Risks

Livagen's clinical safety record in Russian practice is reassuring; Western controlled-safety data does not exist.

• Generally well-tolerated — Russian clinical use has not surfaced major adverse-event signals. The peptide consists of four common amino acids with no unique cytotoxic or immunologic features.
• Mild GI effects (oral) — Occasional mild nausea or GI discomfort with oral capsule dosing; typically transient.
• Injection-site reactions — Mild redness or irritation with SubQ or IM administration.
• Allergic reactions (theoretical) — Rare; no significant reports in the Russian clinical record.
• Theoretical concerns around chromatin modulation — If the central mechanistic claim (heterochromatin decondensation) is accurate, the long-term consequences of unintended gene activation are not characterized. Repeated chronic dosing — beyond the Khavinson-recommended short-course pattern — has no long-term safety data.
• Cancer / proliferation considerations — No signal in the preclinical data, but short-peptide bioregulators that stimulate cell proliferation (hepatocyte regeneration) warrant caution in patients with active malignancy.
• Liver disease of unclear cause — In patients with active viral hepatitis, autoimmune hepatitis, or Wilson disease, unsupervised Livagen use without diagnostic workup is inadvisable — the underlying cause should be identified and treated rather than simply dosing a bioregulator.
• Pregnancy / lactation — Not studied; avoid.
• Drug interactions — No documented significant interactions. Caution with other hepatically-metabolized drugs if chronic dosing alters CYP450 expression as claimed.
• Purity and sourcing — Research-chemical supply varies; require HPLC/MS Certificates of Analysis showing >98% purity.
• Regulatory / quality — The Russian OTC product is regulated as a dietary bioregulator, not a pharmaceutical. Manufacturing standards vary across suppliers.

Bloodwork & Monitoring

• Comprehensive metabolic panel (CMP) — Baseline AST, ALT, alkaline phosphatase, bilirubin, albumin, and total protein. Repeat at end of course to assess hepatic-function changes.
• GGT — Gamma-glutamyl transferase: sensitive hepatobiliary marker.
• Complete blood count (CBC) — Baseline hematologic picture; relevant given Livagen's claimed lymphoid-bioregulator identity.
• Lipid panel — Liver is central to lipoprotein metabolism; baseline and end-of-course comparison is informative.
• Fasting glucose / HbA1c — For patients with fatty-liver-disease overlay where hepatic insulin resistance is a concern.
• Hepatitis viral panel — Baseline screening (HBsAg, HCV antibody) in any patient starting a "hepatoprotective" protocol to exclude treatable primary liver disease.
• Lymphocyte subsets (optional) — CD4 / CD8 / NK cell counts for users interested in tracking lymphoid-bioregulator effects; usually not clinically necessary.
• hsCRP / ferritin — Inflammation and iron status as contextual markers of hepatic health.
• Imaging — For patients with fatty-liver-disease or elevated transaminases of unclear cause, hepatic ultrasound or MRI-PDFF is the standard diagnostic, not Livagen.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

What to Expect — Timeline

No randomized trial has mapped a response curve for synthetic Livagen in humans. The timeline below reflects Khavinson-framework expectations plus aggregated Russian clinical observational reports. Treat it as an informed-guess framing, not a clinical prognosis.

• Days 1–5 — No immediate subjective change. Khavinson bioregulators are framed as slow-onset epigenetic modulators; acute pharmacologic effects are not the expected mechanism.
• Week 1–2 (during the course) — Some users with elevated baseline transaminases or chronic-inflammation overlays report mild subjective improvement — energy, appetite, sleep quality. Objective lab changes are generally not yet visible.
• End of 10–20-day course — End-of-course labs may show modest transaminase normalization in users with baseline elevation. Subjective improvement in users who respond tends to consolidate in this window.
• 2–6 weeks post-course — According to the Khavinson framework, downstream gene-expression changes persist after the peptide has cleared. Users may report continued slow improvement in this "post-course tail" window.
• 3–6 months (between courses) — Subjective benefit often plateaus. Users preparing for a re-cycle typically reassess at this point.
• Re-cycle (2–3 per year) — Standard Khavinson re-cycle cadence. Mechanism claim is that each cycle consolidates the epigenetic reset.
• Non-responders — Substantial. Given the limited clinical evidence, a large fraction of users will see no change across any objective or subjective endpoint. This does not rule out a benefit (effect sizes are plausibly small), but does argue against indefinite continuation in non-responders.
• If you feel worse — Any new or worsening GI symptom, jaundice, rising transaminases, rash, or systemic illness. Stop and investigate. As with any peptide bioregulator, underlying primary disease (viral hepatitis, Wilson disease, autoimmune hepatitis) should be ruled out before attributing symptoms to the bioregulator.

Practical User Notes

• Short courses only — 10–20 days, repeated 2–3 times per year. Continuous daily dosing has no published rationale and diverges from the Khavinson framework.
• Oral is preferred for convenience — Russian retail capsules taken sublingually or swallowed before meals is the most common route. SubQ and IM are used in Russian clinical practice but rarely in self-directed community use.
• Rule out primary liver disease first — Viral hepatitis, autoimmune hepatitis, Wilson disease, hemochromatosis, and NAFLD staging should be addressed before layering a bioregulator. Livagen is not a substitute for diagnostic evaluation of abnormal hepatic labs.
• Fundamentals matter more than the peptide — Alcohol reduction, weight management, Mediterranean-style diet, adequate protein, and glycemic control dominate any effect size a peptide bioregulator could plausibly produce. Don't skip the fundamentals in favor of the peptide.
• Stack with non-peptide adjuncts — NAC, silymarin, vitamin E, Mediterranean diet, and weight management have better-characterized liver-support evidence. Livagen is an optional peptide adjunct, not a foundational intervention.
• Combine with other Khavinson peptides only with framework literacy — The longevity-focused stacking of multiple Khavinson bioregulators is a community practice, not a validated protocol. Users running combined stacks should be familiar with each compound's individual framework.
• Sourcing discipline — Third-party HPLC / MS Certificates of Analysis are the floor. Short peptides are easy to synthesize cleanly but easy to fake — identity verification by mass spec is the standard check.
• Track objective markers, not feelings — AST, ALT, GGT, albumin, and fatty-liver imaging where indicated. Subjective "feel better" is a weak signal; objective lab changes are the honest feedback loop.
• Stop if labs worsen — Rising transaminases, bilirubin, or INR during a Livagen course should prompt immediate cessation and medical evaluation. Do not dose through lab deterioration.
• Consult a clinician with bioregulator literacy — The Western medical community is largely unfamiliar with the Khavinson framework. Work with a physician comfortable with the evidence landscape and willing to monitor objective markers.
• Red flags to stop — Jaundice, severe abdominal pain, altered mental status, GI bleeding, or systemic illness — any of these on a bioregulator cycle are cessation plus immediate evaluation signals.

Regulatory Status

Related Compounds

People researching Livagen often also look at these:

Next Steps

Key References

1. Khavinson VK. Peptides and Ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12374919. (Comprehensive review of the Khavinson short-peptide bioregulator framework, including KEDA / Livagen.)
2. Khavinson VK, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger Publishers; 2005. ISBN 3-8055-7905-5. (Book-length monograph of the Khavinson framework.)
3. Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). 2011;76(11):1210-1219. PMID: 22117546.
4. Khavinson VKh, Lezhava TA, Monaselidze JR, Jokhadze TA, Dvalishvili NA, Bablishvili NK, Trofimova SV. Peptide Epitalon activates chromatin at the old age. Neuroendocrinol Lett. 2003;24(5):329-333. PMID: 14647006. (Chromatin activation framework; Epithalon but same mechanistic framework as Livagen.)
5. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19730006.
6. Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363.
7. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682. (Telomerase claim framework.)
8. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID: 34834147. (Recent programmatic review of Khavinson peptide-DNA interaction framework.)
9. Khavinson VKh, Linkova NS, Umnov RS. Peptide KEDA regulates expression of genes involved in hepatic function and age-related changes of liver tissue. Bull Exp Biol Med. (Russian-language source; English translation available in journal archives.)
10. Khavinson VKh, Malinin VV, Myl'nikov SV. Effect of peptides on lifespan of animals and peptide-dependent gene expression. Bull Exp Biol Med. 2003;135(4):373-375. PMID: 12820081.
11. Morozov VG, Khavinson VKh. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol. 1997;19(9-10):501-505. PMID: 9637344. (Lymphoid-bioregulator framework context for Livagen.)
12. Anisimov VN, Khavinson VKh, Morozov VG. Twenty years of study on effects of pineal peptide preparation: epithalamin in experimental gerontology and oncology. Ann N Y Acad Sci. 1994;719:483-493. PMID: 8010626. (Parent-extract clinical framework.)
13. Khavinson VKh. Tetrapeptide KEDA decondenses heterochromatin in hepatocyte nuclei and modulates liver gene expression. (Khavinson-group experimental work across Russian-language publications, 2007–2012, Bulletin of Experimental Biology and Medicine.)
14. Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Moscow). 2015;80(3):310-322. PMID: 25761685.
15. Fedoreyeva LI, Vanyushin BF. Epigenetic Activity of Short Peptides and Their Interaction with Nucleic Acids. Biol Bull Rev. 2021;11:351-362. (Broader Khavinson-framework review of short-peptide chromatin interactions.)
16. Morozov VG, Khavinson VKh, Kuznik BI. Peptide bioregulators: a new class of geroprotectors. Report 2. Clinical experience. Advances in Gerontology. 2000;5:50-56. (Russian-language clinical experience report.)